BioInsights - A closed, modular approach to autologous CAR T cell therapy manufacturing

A closed, modular approach to autologous CAR T cell therapy manufacturing

Cell & Gene Therapy Insights 2022; 8(8), 1045;

DOI: 10.18609/cgti.2022.154

Published: 14 September 2022
FastFacts
Jason Isaacson

Watch this video to gain an in-depth understanding of Thermo Fisher Scientific’s digitally compatible, GMP-compliant manufacturing platform to produce CAR T cells.

In this video you will see:

  • Preparation of media and reagents used for cell isolation and activation
  • Set up of consumable and instrument for cell processing using the Gibco CTS Rotea Counterflow Centrifugation System
  • Isolation and activation of the cells using the Gibco CTS DynaMag Magnet and CTS Rotea System
  • Transfer of the target cells to the bioreactor using the Thermo Scientific HyPerforma G3Lab controller for culture and lentiviral infection
  • Bead removal, cell wash and concentrate and cryopreservation of the final CAR T cell product

Jason Isaacson is a scientist in the Cell and Gene Therapy business on the Cell Therapy Innovations team at Thermo Fisher Scientific. He is responsible for development and optimization of end-to-end cell therapy workflow solutions that integrate Thermo Fisher’s closed, automated instrumentation platforms. Prior to this role, Jason has gained experience across many industrial environments from large pharma, to small biotech and startups. His extensive experience in research includes 10 years developing HIV small molecule inhibitors, 7 years developing small molecule inhibitors for various oncology targets, and 7 years working with T cell and NK cell therapy development.